Clinical performance of an in-line, ex vivo point-of-care monitor

A multicenter study

Glenn F. Billman, Amy B. Hughes, Golde G. Dudell, Elizabeth Waldman, Lisa M. Adcock, Dan M. Hall, Edmund N. Orsini, Adolph Koska, Linda J. Van Marter, Neil N. Finer, Jeff C. Kulhavy, Ronald D. Feld, John A. Widness

Research output: Contribution to journalArticle

10 Citations (Scopus)

Abstract

Background: The management of critically ill infants and neonates includes frequent determination of arterial blood gas, electrolyte, and hematocrit values. An objective of attached point-of-care patient monitoring is to provide clinically relevant data without the adverse consequences associated with serial phlebotomy. Methods: We prospectively determined the mean difference (and SD of the difference) from laboratory methods of an in-line, ex vivo monitor, the VIA LVM Blood Gas and Chemistry Monitoring System® (VIA LVM Monitor; Metracor Technologies, Inc.), in 100 critically ill neonates and infants at seven children's hospitals. In doing so, we examined monitor stability with continuous use. In vivo patient test results from laboratory benchtop analyzers were compared with those from the VIA LVM Monitor on paired samples. In a separate in vitro comparison, benchtop analyzer and monitor test results were compared on whole-blood split samples. Results: A total of 1414 concurrent, paired-sample measurements were obtained. The mean differences (SD of differences) from laboratory methods and r values for the combined data for the VIA LVM Monitor from the seven sites were 0.001 (0.026) and 0.97 for pH, 0.7 (3.6) mmHg and 0.94 for PCO2, 4.2 (9.6) mmHg and 0.98 for PO2, 0.0 (2.9) mmol/L and 0.87 for sodium, 0.1 (0.2) mmol/L and 0.96 for potassium, and 0.3% (2.9%) and 0.90 for hematocrit. Performance results were similar among the study sites with increasing time of monitor use and between in vivo paired-sample and in vitro split-sample test results. Conclusion: The VIA LVM Monitor can be used to assess critically ill neonates and infants.

Original languageEnglish (US)
Pages (from-to)2030-2043
Number of pages14
JournalClinical Chemistry
Volume48
Issue number11
StatePublished - Nov 1 2002
Externally publishedYes

Fingerprint

Point-of-Care Systems
Critical Illness
Multicenter Studies
Blood
Newborn Infant
Hematocrit
Gases
Patient monitoring
Phlebotomy
Physiologic Monitoring
Electrolytes
Potassium
Sodium
Technology
Monitoring
In Vitro Techniques

ASJC Scopus subject areas

  • Clinical Biochemistry

Cite this

Billman, G. F., Hughes, A. B., Dudell, G. G., Waldman, E., Adcock, L. M., Hall, D. M., ... Widness, J. A. (2002). Clinical performance of an in-line, ex vivo point-of-care monitor: A multicenter study. Clinical Chemistry, 48(11), 2030-2043.

Clinical performance of an in-line, ex vivo point-of-care monitor : A multicenter study. / Billman, Glenn F.; Hughes, Amy B.; Dudell, Golde G.; Waldman, Elizabeth; Adcock, Lisa M.; Hall, Dan M.; Orsini, Edmund N.; Koska, Adolph; Van Marter, Linda J.; Finer, Neil N.; Kulhavy, Jeff C.; Feld, Ronald D.; Widness, John A.

In: Clinical Chemistry, Vol. 48, No. 11, 01.11.2002, p. 2030-2043.

Research output: Contribution to journalArticle

Billman, GF, Hughes, AB, Dudell, GG, Waldman, E, Adcock, LM, Hall, DM, Orsini, EN, Koska, A, Van Marter, LJ, Finer, NN, Kulhavy, JC, Feld, RD & Widness, JA 2002, 'Clinical performance of an in-line, ex vivo point-of-care monitor: A multicenter study', Clinical Chemistry, vol. 48, no. 11, pp. 2030-2043.
Billman GF, Hughes AB, Dudell GG, Waldman E, Adcock LM, Hall DM et al. Clinical performance of an in-line, ex vivo point-of-care monitor: A multicenter study. Clinical Chemistry. 2002 Nov 1;48(11):2030-2043.
Billman, Glenn F. ; Hughes, Amy B. ; Dudell, Golde G. ; Waldman, Elizabeth ; Adcock, Lisa M. ; Hall, Dan M. ; Orsini, Edmund N. ; Koska, Adolph ; Van Marter, Linda J. ; Finer, Neil N. ; Kulhavy, Jeff C. ; Feld, Ronald D. ; Widness, John A. / Clinical performance of an in-line, ex vivo point-of-care monitor : A multicenter study. In: Clinical Chemistry. 2002 ; Vol. 48, No. 11. pp. 2030-2043.
@article{ea2f10912d594fb0a6114c000e0610d0,
title = "Clinical performance of an in-line, ex vivo point-of-care monitor: A multicenter study",
abstract = "Background: The management of critically ill infants and neonates includes frequent determination of arterial blood gas, electrolyte, and hematocrit values. An objective of attached point-of-care patient monitoring is to provide clinically relevant data without the adverse consequences associated with serial phlebotomy. Methods: We prospectively determined the mean difference (and SD of the difference) from laboratory methods of an in-line, ex vivo monitor, the VIA LVM Blood Gas and Chemistry Monitoring System{\circledR} (VIA LVM Monitor; Metracor Technologies, Inc.), in 100 critically ill neonates and infants at seven children's hospitals. In doing so, we examined monitor stability with continuous use. In vivo patient test results from laboratory benchtop analyzers were compared with those from the VIA LVM Monitor on paired samples. In a separate in vitro comparison, benchtop analyzer and monitor test results were compared on whole-blood split samples. Results: A total of 1414 concurrent, paired-sample measurements were obtained. The mean differences (SD of differences) from laboratory methods and r values for the combined data for the VIA LVM Monitor from the seven sites were 0.001 (0.026) and 0.97 for pH, 0.7 (3.6) mmHg and 0.94 for PCO2, 4.2 (9.6) mmHg and 0.98 for PO2, 0.0 (2.9) mmol/L and 0.87 for sodium, 0.1 (0.2) mmol/L and 0.96 for potassium, and 0.3{\%} (2.9{\%}) and 0.90 for hematocrit. Performance results were similar among the study sites with increasing time of monitor use and between in vivo paired-sample and in vitro split-sample test results. Conclusion: The VIA LVM Monitor can be used to assess critically ill neonates and infants.",
author = "Billman, {Glenn F.} and Hughes, {Amy B.} and Dudell, {Golde G.} and Elizabeth Waldman and Adcock, {Lisa M.} and Hall, {Dan M.} and Orsini, {Edmund N.} and Adolph Koska and {Van Marter}, {Linda J.} and Finer, {Neil N.} and Kulhavy, {Jeff C.} and Feld, {Ronald D.} and Widness, {John A.}",
year = "2002",
month = "11",
day = "1",
language = "English (US)",
volume = "48",
pages = "2030--2043",
journal = "Clinical Chemistry",
issn = "0009-9147",
publisher = "American Association for Clinical Chemistry Inc.",
number = "11",

}

TY - JOUR

T1 - Clinical performance of an in-line, ex vivo point-of-care monitor

T2 - A multicenter study

AU - Billman, Glenn F.

AU - Hughes, Amy B.

AU - Dudell, Golde G.

AU - Waldman, Elizabeth

AU - Adcock, Lisa M.

AU - Hall, Dan M.

AU - Orsini, Edmund N.

AU - Koska, Adolph

AU - Van Marter, Linda J.

AU - Finer, Neil N.

AU - Kulhavy, Jeff C.

AU - Feld, Ronald D.

AU - Widness, John A.

PY - 2002/11/1

Y1 - 2002/11/1

N2 - Background: The management of critically ill infants and neonates includes frequent determination of arterial blood gas, electrolyte, and hematocrit values. An objective of attached point-of-care patient monitoring is to provide clinically relevant data without the adverse consequences associated with serial phlebotomy. Methods: We prospectively determined the mean difference (and SD of the difference) from laboratory methods of an in-line, ex vivo monitor, the VIA LVM Blood Gas and Chemistry Monitoring System® (VIA LVM Monitor; Metracor Technologies, Inc.), in 100 critically ill neonates and infants at seven children's hospitals. In doing so, we examined monitor stability with continuous use. In vivo patient test results from laboratory benchtop analyzers were compared with those from the VIA LVM Monitor on paired samples. In a separate in vitro comparison, benchtop analyzer and monitor test results were compared on whole-blood split samples. Results: A total of 1414 concurrent, paired-sample measurements were obtained. The mean differences (SD of differences) from laboratory methods and r values for the combined data for the VIA LVM Monitor from the seven sites were 0.001 (0.026) and 0.97 for pH, 0.7 (3.6) mmHg and 0.94 for PCO2, 4.2 (9.6) mmHg and 0.98 for PO2, 0.0 (2.9) mmol/L and 0.87 for sodium, 0.1 (0.2) mmol/L and 0.96 for potassium, and 0.3% (2.9%) and 0.90 for hematocrit. Performance results were similar among the study sites with increasing time of monitor use and between in vivo paired-sample and in vitro split-sample test results. Conclusion: The VIA LVM Monitor can be used to assess critically ill neonates and infants.

AB - Background: The management of critically ill infants and neonates includes frequent determination of arterial blood gas, electrolyte, and hematocrit values. An objective of attached point-of-care patient monitoring is to provide clinically relevant data without the adverse consequences associated with serial phlebotomy. Methods: We prospectively determined the mean difference (and SD of the difference) from laboratory methods of an in-line, ex vivo monitor, the VIA LVM Blood Gas and Chemistry Monitoring System® (VIA LVM Monitor; Metracor Technologies, Inc.), in 100 critically ill neonates and infants at seven children's hospitals. In doing so, we examined monitor stability with continuous use. In vivo patient test results from laboratory benchtop analyzers were compared with those from the VIA LVM Monitor on paired samples. In a separate in vitro comparison, benchtop analyzer and monitor test results were compared on whole-blood split samples. Results: A total of 1414 concurrent, paired-sample measurements were obtained. The mean differences (SD of differences) from laboratory methods and r values for the combined data for the VIA LVM Monitor from the seven sites were 0.001 (0.026) and 0.97 for pH, 0.7 (3.6) mmHg and 0.94 for PCO2, 4.2 (9.6) mmHg and 0.98 for PO2, 0.0 (2.9) mmol/L and 0.87 for sodium, 0.1 (0.2) mmol/L and 0.96 for potassium, and 0.3% (2.9%) and 0.90 for hematocrit. Performance results were similar among the study sites with increasing time of monitor use and between in vivo paired-sample and in vitro split-sample test results. Conclusion: The VIA LVM Monitor can be used to assess critically ill neonates and infants.

UR - http://www.scopus.com/inward/record.url?scp=18644366650&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=18644366650&partnerID=8YFLogxK

M3 - Article

VL - 48

SP - 2030

EP - 2043

JO - Clinical Chemistry

JF - Clinical Chemistry

SN - 0009-9147

IS - 11

ER -